|
1
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Campbell PJ, Yachida S, Mudie LJ, et al:
The patterns and dynamics of genomic instability in metastatic
pancreatic cancer. Nature. 467:1109–1113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herrmann R and Jelic S: Pancreatic cancer:
ESMO clinical recommendations for diagnosis, treatment and
follow-up. Ann Oncol. 19(Suppl 2): I25–I26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosewicz S and Wiedenmann B: Pancreatic
carcinoma. Lancet. 349:485–489. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burris HR, Moore MJ, Andersen J, et al:
Improvements in survival and clinical benefit with gemcitabine as
first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
6
|
Ou YQ, Zhu W, Li Y, et al: Aspirin
inhibits proliferation of gemcitabine-resistant human pancreatic
cancer cells and augments gemcitabine-induced cytotoxicity. Acta
Pharmacol Sin. 31:73–80. 2010. View Article : Google Scholar
|
|
7
|
Ina S, Hirono S, Noda T and Yamaue H:
Identifying molecular markers for chemosensitivity to gemcitabine
in pancreatic cancer: increased expression of interferon-stimulated
gene 15 kDa is associated with intrinsic chemoresistance. Pancreas.
39:473–485. 2010. View Article : Google Scholar
|
|
8
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
9
|
Liu J: Oleanolic acid and ursolic acid:
research perspectives. J Ethnopharmacol. 100:92–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu J: Pharmacology of oleanolic acid and
ursolic acid. J Ethnopharmacol. 49:57–68. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shih YH, Chein YC, Wang JY and Fu YS:
Ursolic acid protects hippocampal neurons against kainate-induced
excitotoxicity in rats. Neurosci Lett. 362:136–140. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chung YK, Heo HJ, Kim EK, et al:
Inhibitory effect of ursolic acid purified from Origanum majorana L
on the acetylcholinesterase. Mol Cells. 11:137–143. 2001.PubMed/NCBI
|
|
13
|
Tsai SJ and Yin MC: Antioxidative and
anti-inflammatory protection of oleanolic acid and ursolic acid in
PC12 cells. J Food Sci. 73:H174–H178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Somova LO, Nadar A, Rammanan P and Shode
FO: Cardiovascular, antihyperlipidemic and antioxidant effects of
oleanolic and ursolic acids in experimental hypertension.
Phytomedicine. 10:115–121. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cha HJ, Bae SK, Lee HY, et al:
Anti-invasive activity of ursolic acid correlates with the reduced
expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human
fibrosarcoma cells. Cancer Res. 56:2281–2284. 1996.PubMed/NCBI
|
|
16
|
Zhang Y, Kong C, Zeng Y, et al: Ursolic
acid induces PC-3 cell apoptosis via activation of JNK and
inhibition of Akt pathways in vitro. Mol Carcinog. 49:374–385.
2010.PubMed/NCBI
|
|
17
|
Yang L, Liu X, Lu Z, et al: Ursolic acid
induces doxorubicin-resistant HepG2 cell death via the release of
apoptosis-inducing factor. Cancer Lett. 298:128–138. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xavier CP, Lima CF, Preto A, Seruca R,
Fernandes-Ferreira M and Pereira-Wilson C: Luteolin, quercetin and
ursolic acid are potent inhibitors of proliferation and inducers of
apoptosis in both KRAS and BRAF mutated human colorectal cancer
cells. Cancer Lett. 281:162–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Manu KA and Kuttan G: Ursolic acid induces
apoptosis by activating p53 and caspase-3 gene expressions and
suppressing NF-kappaB mediated activation of bcl-2 in B16F-10
melanoma cells. Int Immunopharmacol. 8:974–981. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang JS, Ren TN and Xi T: Ursolic acid
induces apoptosis by suppressing the expression of FoxM1 in MCF-7
human breast cancer cells. Med Oncol. 29:10–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu W, Ou Y, Li Y, et al: A small-molecule
triptolide suppresses angiogenesis and invasion of human anaplastic
thyroid carcinoma cells via down-regulation of the nuclear
factor-kappa B pathway. Mol Pharmacol. 75:812–819. 2009. View Article : Google Scholar
|
|
22
|
Li J, Zhu W, Leng T, et al:
Triptolide-induced cell cycle arrest and apoptosis in human renal
cell carcinoma cells. Oncol Rep. 25:979–987. 2011.PubMed/NCBI
|
|
23
|
He D, Xu Q, Yan M, et al: The NF-kappaB
inhibitor, celastrol, could enhance the anti-cancer effect of
gambogic acid on oral squamous cell carcinoma. BMC Cancer.
9:3432009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stairs DB, Nakagawa H, Klein-Szanto A, et
al: Cdx1 and c-Myc foster the initiation of transdifferentiation of
the normal esophageal squamous epithelium toward Barrett's
esophagus. PLoS One. 3:e35342008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia Y, Liu Y, Wan J, et al: Novel triazole
ribonucleoside down-regulates heat shock protein 27 and induces
potent anticancer activity on drug-resistant pancreatic cancer. J
Med Chem. 52:6083–6096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jonckheere N, Fauquette V, Stechly L, et
al: Tumour growth and resistance to gemcitabine of pancreatic
cancer cells are decreased by AP-2alpha overexpression. Br J
Cancer. 101:637–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyamoto H, Murakami T, Tsuchida K, Sugino
H, Miyake H and Tashiro S: Tumor-stroma interaction of human
pancreatic cancer: acquired resistance to anticancer drugs and
proliferation regulation is dependent on extracellular matrix
proteins. Pancreas. 28:38–44. 2004. View Article : Google Scholar
|
|
28
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang YX, Kong CZ, Wang LH, et al: Ursolic
acid overcomes Bcl-2-mediated resistance to apoptosis in prostate
cancer cells involving activation of JNK-induced Bcl-2
phosphorylation and degradation. J Cell Biochem. 109:764–773.
2010.PubMed/NCBI
|
|
30
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Falasca M: PI3K/Akt signalling pathway
specific inhibitors: a novel strategy to sensitize cancer cells to
anti-cancer drugs. Curr Pharm Des. 16:1410–1416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arlt A, Gehrz A, Muerkoster S, et al: Role
of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma
cell lines against gemcitabine-induced cell death. Oncogene.
22:3243–3251. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang X, Yang Y, Xu C, et al: CHFR
suppression by hypermethylation sensitizes endometrial cancer cells
to paclitaxel. Int J Gynecol Cancer. 21:996–1003. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lange TS, Kim KK, Singh RK, Strongin RM,
McCourt CK and Brard L: Iron(III)-salophene: an organometallic
compound with selective cytotoxic and anti-proliferative properties
in platinum-resistant ovarian cancer cells. PLoS One. 3:e23032008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Welch SA and Moore MJ: Combination
chemotherapy in advanced pancreatic cancer: time to raise the white
flag? J Clin Oncol. 25:2159–2161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mamaghani S, Patel S and Hedley DW:
Glycogen synthase kinase-3 inhibition disrupts nuclear
factor-kappaB activity in pancreatic cancer, but fails to sensitize
to gemcitabine chemotherapy. BMC Cancer. 9:1322009. View Article : Google Scholar
|
|
37
|
Shan JZ, Xuan YY, Ruan SQ and Sun M:
Proliferation-inhibiting and apoptosis-inducing effects of ursolic
acid and oleanolic acid on multi-drug resistance cancer cells in
vitro. Chin J Integr Med. 17:607–611. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weston CR and Davis RJ: The JNK signal
transduction pathway. Curr Opin Cell Biol. 19:142–149. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perugini RA, McDade TP, Vittimberga FJ and
Callery MP: Pancreatic cancer cell proliferation is
phosphatidylinositol 3-kinase dependent. J Surg Res. 90:39–44.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang YX, Kong CZ, Wang HQ, Wang LH, Xu CL
and Sun YH: Phosphorylation of Bcl-2 and activation of caspase-3
via the c-Jun N-terminal kinase pathway in ursolic acid-induced
DU145 cells apoptosis. Biochimie. 91:1173–1179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kroemer G and Reed JC: Mitochondrial
control of cell death. Nat Med. 6:513–519. 2000. View Article : Google Scholar
|
|
42
|
Ashkenazi A and Dixit VM: Death receptors:
signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Teraishi F, Zhang L, Guo W, et al:
Activation of c-Jun NH2-terminal kinase is required for
gemcitabine's cytotoxic effect in human lung cancer H1299 cells.
FEBS Lett. 579:6681–6687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Garcia-Echeverria C and Sellers WR: Drug
discovery approaches targeting the PI3K/Akt pathway in cancer.
Oncogene. 27:5511–5526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kane LP, Shapiro VS, Stokoe D and Weiss A:
Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol. 9:601–604.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mayo LD and Donner DB: A
phosphatidylinositol 3-kinase/Akt pathway promotes translocation of
Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA.
98:11598–11603. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and
Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2
phosphorylation. Nat Cell Biol. 3:973–982. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis
and subcellular localization. Genes Dev. 12:3499–3511. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pham NA, Tsao MS, Cao P and Hedley DW:
Dissociation of gemcitabine sensitivity and protein kinase B
signaling in pancreatic ductal adenocarcinoma models. Pancreas.
35:E16–E26. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ng SS, Tsao MS, Nicklee T and Hedley DW:
Wortmannin inhibits pkb/akt phosphorylation and promotes
gemcitabine antitumor activity in orthotopic human pancreatic
cancer xenografts in immunodeficient mice. Clin Cancer Res.
7:3269–3275. 2001.PubMed/NCBI
|
|
52
|
Sultana N: Clinically useful anticancer,
antitumor, and antiwrinkle agent, ursolic acid and related
derivatives as medicinally important natural product. J Enzyme
Inhib Med Chem. 26:616–642. 2011. View Article : Google Scholar
|
